insights_auto
6160 주가가 상승한 이유: 4.36%?
자세히 알아보기chevron_right
6160:HKG
베이진
HK$225.00
arrow_upward
+4.36%(+9.40) 1D
10월 16일, 오후 4시 8분 14초 GMT+8 · HKD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto6160의 주요 통계 생성 중...
시가
HK$224.80
고가
HK$230.20
저가
HK$221.80
시가총액
3557.63억
평균 거래량
292.98만
거래량
441.39만
주가수익률
65.67
52주 최고가
HK$235.60
52주 최저가
HK$153.00
EPS
HK$3.43
유통 주식수
14.26억
직원 수
1만
시가
HK$224.80
고가
HK$230.20
저가
HK$221.80
시가총액
3557.63억
평균 거래량
292.98만
거래량
441.39만
주가수익률
65.67
52주 최고가
HK$235.60
52주 최저가
HK$153.00
EPS
HK$3.43
유통 주식수
14.26억
직원 수
1만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
ad-hoc-news.de
·
10시간 전
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
프로필
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
베이진에 관한 정보